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Thad recently commented publicly that “when troponin was
lousy assay it was a great test, but now that it’s becoming
great assay, it’s getting to be a lousy test.” And my penance
or that utterance is to write this editorial.
So, let’s think about that statement . . .
What constitutes a great laboratory test? Is it something
nherent or unique in the data themselves? Is it the infor-
ation that it provides? Or, is it the knowledge that it
rings, and by that I mean, does it provide information that
an be put to productive use? Said bluntly, does knowing a
articular test result impact our decision making in some
ubstantive way, or change how we would manage the
atient? Does it have a clear and measurable clinical
mplication?
See page 2118
And what constitutes a great assay? Is it the accuracy of
he result or the reproducibility of the number? Is it the
oefficient of variability (CV), and at what cut point is this
mportant? (We have declared that the ideal troponin [Tn]
ssay will have a CV of 10% at or below the 99th
ercentile cutoff) (1). But how do we determine the appro-
riate population from which to derive that 99th percentile?
s it 1-size-fits-all, or does it need to be parsed by age, sex,
ace, body mass, and so forth? Are there temporal con-
traints such that value of the information decays over time?
n other words, how important is turnaround time?
Finally, what is the clinical context for which the test was
erformed? Does the cutoff value change, or is it impacted
y specific clinical circumstances? Would the reference
anges be different if the values were measured in true
ormals, versus all persons presenting to the emergency
epartment, versus only those who were being admitted for
resumed acute coronary syndromes? Couch potatoes versus
arathoners? Symptomatic versus asymptomatic? History
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.h
From the Veterans Health Administration, Virginia Commonwealth University
ealth System, Richmond, Virginia.f coronary disease versus none? And, how do we manage
roblems introduced by comorbidities such as renal failure?
The answers to much of the above can be learned from
ooking at the history of Tn development over the past 2
ecades.
history lesson. CHAPTER 1. When the early cardiac
roponin T (TnT) and troponin I (TnI) assays were first
eing evaluated in the early 1990s, the initial target popu-
ations invariably included patients presenting with ST-
egment elevation myocardial infarction (MI). A good
ohort to study, but irrelevant clinically as the laboratory test
ad virtually no added value in this population since the
iagnosis had been made based on, and the clinical action
ictated by, the presenting electrocardiogram (ECG [ST-
egment elevation MI]). Then an interesting finding arose:
lthough TnT and TnI were confirmed to be specific to the
yocardium, the specificity of the assays was poor relative to
xpectations. In the landmark study by Katus et al. (2),
espite very high sensitivity, the specificity of TnT for acute
I was only 78% when using a cutoff of 0.5 g/l. However,
f patients with the clinical diagnosis of unstable angina
ere excluded from the calculation, the specificity improved
o 95%. Why? Simply because the gold standard, creatine
inase-myocardial band (CK-MB), was an imperfect stan-
ard. Why? Because the reference standard, CK-MB mass
ssay, measured the normal population distribution, and the
ormal population distribution is very broad, resulting in a
elatively high 99th percentile cutoff value. (It could also be
onfounded by the presence of skeletal muscle damage.)
his allowed for detectable Tn in patients who had “nor-
al” CK-MB levels, even with the relatively insensitive
arly assays. The obvious conclusion must be that either
here are false positive Tn values, or that Tn is more
ensitive than CK-MB. This has been answered by the
eproducible observation that patients who have positive Tn
ut negative CK-MB on average have worse outcomes
ompared to patients who are also Tn negative (3).
history lesson. CHAPTER 2. The discordance between Tn
nd CK-MB was initially addressed in the context of
xisting definitions. The logical conclusion at first was that
n could diagnose unstable angina (i.e., acute ischemic
eart disease with MI ruled out by serial negative CK-
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Value of an Assay Versus That of a Test May 11, 2010:2125–8Bs). As an initial attempt to reconcile this, in 1999 the
ational Academy of Clinical Biochemistry published the
tandards of Laboratory Practice recommending 2 cutoffs
or Tn (4). The first was at the 95th percentile, which for
he first-generation assays roughly correlated to the
K-MB cutoffs, and would be diagnostic of acute MI. The
econd would be at the 99th percentile, or lower limit of
etectability. That range between this lower cutoff and the
diagnostic” cutoff was frequently referred to at the time as
“gray zone,” but since it did provide clear prognostic
nformation, the feeling was that it should be formally
ecognized, and a new diagnostic category was recom-
ended: “minor myocardial damage” and “minimal myo-
ardial injury” were terms frequently being offered at the
ime. A different approach was taken in 2000 by the
uropean Society of Cardiology/American College of Car-
iology Joint Committee on the Redefinition of Myocardial
nfarction (1). The new definition was “myocardial necrosis
aused by ischemia,” and it designated Tn as the “preferred”
iochemical marker for detecting necrosis, noting that it
ad “ . . . nearly absolute myocardial tissue specificity, as
ell as high sensitivity. . . .” It went on to set the cutoff at
he 99th percentile, but cautioned that the acceptable
mprecision (the CV) at this cutoff should be 10%. This
as followed shortly by an editorial from Jaffe et al. (5),
rguing that “it’s time for a change to a troponin standard.”
history lesson. CHAPTER 3. The first-generation Tn
ssays were relatively insensitive. The second-generations
n assays were more sensitive, but still relatively insensitive.
he third-generation Tn assays are even more sensitive, and
es, still relatively insensitive. An important consideration is
hat as the assays have improved in their sensitivity, the
nalytical performance has also been improving. So as to not
elabor the point, we will accept as true the premise that any
etectable Tn by current commercial assays is in fact
ndicative of irreversible myocardial injury, and as such
arries prognostic information. However, there are now
merging state-of-the-art research assays that can measure
n in the normal population, including the individual
ay-to-day variability (6). These are what I would consider
s highly sensitive assays. Up to this point, the absence of
etectable Tn was considered “normal,” and with each
uccessive iteration of the assay, the normal level was reset.
ut soon, for the first time, we will actually be able to
easure a normal Tn in clinical practice. This is a mixed
lessing: whereas the 99th percentile will actually be a true
epresentation of the normal population, we will soon have
o make decisions about what reference population is
ppropriate. In effect, Tn will then be like CK-MB was, and
e will have to seriously consider the relationship of age,
ody mass, sex, comorbidities, and so forth, when interpret-
ng the data. In effect, Tn has appeared to be a very sensitive
ssay simply because it was more sensitive than CK-MB,
he existing but flawed gold standard at the time. However,
egardless of the diagnostic cutoff, with each successive
mprovement in the assay, the fundamental hypothesis that hyocardial necrosis is a bad prognostic indicator has held
ast.
Which brings us, finally, to the article by Bonaca et al. (7)
n this issue of the Journal describing the prognostic rela-
ionship of a “current generation” Tn assay in patients
resenting with presumed acute coronary syndromes who
ere enrolled in the MERLIN–TIMI 36 (Metabolic Effi-
iency With Ranolazine for Less Ischemia in Non-ST
levation Acute Coronary–Thrombolysis In Myocardial
nfarction 36) trial. The assay used was TnI-Ultra (ADVIA
entaur, Siemens Healthcare Diagnostics, Deerfield, Illi-
ois), which has a lower limit of detection at 0.006 g/l, and
he 99th percentile reference limit at 0.04 g/l with a 10%
V at 0.03 g/l. In a nutshell, patients with TnI 0.04
g/l and0.1 g/l had significantly more adverse outcomes
death/MI) at 30 days and 1 year compared with patients
ith 0.04 g/l, thus confirming the prognostic signifi-
ance of an ever-lower Tn cutoff using an ultrasensitive
ssay with good performance characteristics. (In fairness, it
hould be mentioned that there was not a statistical adverse
utcome demonstrated for patients in the range 0.04 g/l
nd the lower limit of detection, 0.006 g/l.)
history lesson. CHAPTER 4. Despite the redefinition of
I to a Tn standard, detection of Tn alone does not equal
he diagnosis of MI. The redefinition of myocardial infarc-
ion (1) explicitly states that only myocardial necrosis
econdary to ischemia constitutes a MI. To further compli-
ate matters, not all MIs (Tn elevations secondary to
schemia) are due to acute coronary syndromes. To address
his and the particularly confusing issue of procedural Tn
levations, the “universal definition of myocardial infarc-
ion” was published in 2007 by the joint European Society
f Cardiology/American College of Cardiology/American
eart Association/World Heart Federation (ESD/ACCF/
HA/WHF) task force on the redefinition of myocardial
nfarction (8). This describes the 5 categories of MI inclu-
ive of sudden death, the typical acute coronary syndrome,
ther supply-demand mismatch situations, and procedural
nfarcts (both percutaneous coronary intervention and cor-
nary artery bypass graft surgery). Absent an improvement
n our ability to detect ischemia, the increasingly sensitive
n assays will continue to challenge the distinction between
I and other etiologies of myocardial necrosis.
In that regard, it should be noted that the study by
onaca et al. (7) was performed in a highly selected and
nriched population. Entry criteria defined those enrolled as
aving unstable angina on the basis of either objective data,
ECG, biomarkers), or at high risk for it (diabetes mellitus,
IMI risk score). This is important because any positive Tn
ould not be unexpected, and thus would be assumed at
ace value to be true, and hence diagnostic of MI. The other
ssue is that the Tn obtained is a single point value drawn
ometime after enrollment, which was an average of 23 h
fter the onset of symptoms. While this may or may not
ave an implication on the results of the study per se, it
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May 11, 2010:2125–8 Value of an Assay Versus That of a Testould be an important consideration in the clinical assess-
ent of a patient in the emergency department.
history lesson. CHAPTER 5, MODERN TIMES (2010). Al-
hough the diagnosis of MI is now crystal clear and based on
Tn standard, we have done little to resolve the confusion
round nonischemic Tn elevations. These are frequently
eferred to as “false positive troponins”—or by some as
‘expletive’ false positive troponins.” The consequence of ever
ore sensitive assays will be the finding of more and more
atients with small Tn elevations lacking the supportive clinical
ndings to assign the diagnosis of MI. This is compounded by
he tendency to order Tn tests on increasing numbers of
atients lacking clinical signs or symptoms suggestive of acute
oronary events (those with a low pre-test probability). The
esult is an increasing number of undifferentiated patients with
ow-level Tn elevations, and consequently, a growing distrust
f the test by many practitioners who fail to appreciate the
linical significance of the findings absent a diagnosis of MI.
irst and foremost, we must always remember that elevated Tn
oes not necessarily equate to an acute coronary event, and it
as been that singular issue that accounts for most of the
onfusion.
And herein lays the crux of the issue: what is the added
alue of a positive Tn finding? Make no mistake, while the
nding of elevated Tn imparts prognostic information,
nowing that information does not necessarily change the
linical approach to the patient in a way that improves care
r outcome. In fact, one could argue that many of the
urrent low-level Tn results may in fact negatively impact
atient care by promoting over-reaction on the part of
linicians. Said simply, when it comes to Tn, and for that
atter, all cardiac biomarkers, it is easy to show prognosis;
t is very difficult to show prognostic value. This is true in
art because prognosis is generally demonstrated in large
opulations, and prognostic value relates to clinical effects
n individual patients.
In the original World Health Organization definition of
I, published in 1979, the diagnostic criteria were based on
he triad of ECG, clinical findings, and serial cardiac
nzymes (9). A major consequence of the increasingly
ensitive and specific Tn in the context of the “redefinition
o a troponin standard” has been the erosion of the impor-
ance of the clinical findings, a diminished value of the
CG, and most importantly a marginalization of the value
f serial biomarker measurements. As the Tn assays become
ore and more sensitive, and analytical performance im-
roves, the clinical context in which results are interpreted
ill be increasingly important.
history lesson. CHAPTER 6. The more things change the
ore they stay the same. In addition to factoring in the
CG and clinical situation when making a diagnosis of MI,
he temporal rise and fall in cardiac markers remains an
mportant component of the diagnosis. This dates back to
he original WHO definition, and has been reiterated in
oth the 2000 ESC/ACC myocardial infarction redefined
onsensus paper and again by the universal definition of
ryocardial infarction ESD/ACCF/AHA/WHF task force.
r. Jaffe has been reminding us for well over 10 years about
he importance of the temporal information derived from
erial biomarker measurements. This was very eloquently
eiterated as the key to differentiating low-level Tn eleva-
ions for the diagnosis of an acute coronary event versus
rognostic implications in other conditions in a 2006
ditorial entitled “How low can you go if you can see the
ise?” (10). This was an important prognostication; as
he current generation assays have become more and
ore sensitive and have improved analytical characteris-
ics, the discrimination between Tn elevations that rep-
esent acute coronary events versus other pathological
onditions will be based on the temporal changes and/or
nterpretation of the clinical findings. So, for instance, in
ome renal failure patients, a small Tn elevation that rises
nd falls back to baseline over 8 to 12 h may represent a
I, whereas a small elevation that remains constant over
everal days will likely not.
In conclusion, when Tn was a lousy assay, it really was a
reat test because when used in the appropriate context it
arkedly improved on the existing gold standard, CK-MB,
or the diagnosis of MI. In effect, the diagnosis of MI had
ecome a technical decision based predominantly on a
aboratory result because of its apparent sensitivity and
ighly reliable cardiac specificity. However, as the Tn assays
ave improved, both in threshold of detection and with
mprecision, higher sensitivity has become a double-edged
word. While the prognostic value of an elevated Tn
ontinues to appear valid regardless of how low the thresh-
ld at which we are able to detect it—as is again demon-
trated for the latest generation Tn assay by Bonaca et al.
7)—we will most certainly find more and more clinical
nstances where Tn can be detected outside of situations
hat clinically constitute MI. That will continue until such
ime as commercial assays are accurately measuring Tn
n the true normal range with acceptable CVs. At that point,
n will truly be a great assay, and it may well then be a really
ousy test unless we can factor in “true normal” when
nterpreting the result. And at that time, the diagnosis of
I will again become a cognitive decision integrating both
bjective and clinical data.
But for now, as long as the absence of Tn is the only
ormal, and a positive Tn can confidently be considered
bnormal, it will likely continue to contribute to prognosis
egardless of etiology. With each subsequent improvement
o the Tn assay, the question then will be, as it is now: does
t continue to provide prognostic value? That alone is the
rue measure of a great test.
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